Dear Ms. Dohanish:

Please refer to your supplemental new drug application dated March 27, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Tracleer (bosentan) 62.5 and 125 mg Tablets.

This “Changes Being Effected” supplemental new drug application provides for revisions to the Black Box Warning and Adverse Reactions (Post-Marketing Experience) sections of the approved package insert and the medication guide.

We have completed our review of this supplemental new drug application. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text. The final printed labeling (FPL) must be identical to labeling submitted March 27, 2007.

We received the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/oc/datacouncil/spl.html. We will transmit that version to the National Library of Medicine for public dissemination.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Dan Brum, Pharm.D., Regulatory Health Project Manager, at (301)796-0578.
Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Norman Stockbridge
6/1/2007 02:03:00 PM